Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

SZSijun ZhangYLYaqing LiFZFangrong Zong

Discussion

Loading...

Member takes

Overview

Observational analysis shows circulating tumor DNA impacts treatment response in B-cell lymphomas, indicating potential for prognosis assessment.

Key Points

  • Circulating tumor DNA detected through low-pass whole-genome sequencing improves prognosis evaluation.
  • A total of 33 peripheral blood samples tracked treatment response and residual disease in 11 patients.
  • Analysis of tumor fraction values revealed a relationship with complete response rates after treatment.
  • Supports the use of ctDNA for risk stratification during CAR-T cell therapy in lymphoma patients.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d56fhttps://doi.org/10.1182/blood-2025-7060
View Full Paper
Ask AI
Bookmark
Share